In
the study, published in the research journal Scientific Reports,
researchers succeeded in reducing epileptic activity in the hippocampus,
an area of the brain which is important for memory and learning, among
other things. In the most severe cases, this is exactly the part of the
brain where epileptic seizures usually start.
The researchers used a method known as chemogenetics**, which enables them to reduce activity in the specific areas and nerve cells involved in an epileptic seizure, whereas other parts and cells in the body remain unaffected. This is in contrast to current drugs that affect more or less all parts and cells of the body, potentially leading to side-effects.
“Very few similar studies have been carried out previously, and this is the first study in which we succeeded in reducing the epileptic activity in one area of the brain by using chemogenetics to affect another area, not the seizure focus. This opens up the possibility of treating epilepsy in areas of the brain that cannot be surgically removed or treated directly”, explains Mérab Kokaia.
In Sweden, around 60 000 people currently suffer from epilepsy, of whom around a third have such a severe form of the disease that current treatment with existing drugs does not work.
“We hope that, in the future, this knowledge will help people with this severe form of epilepsy, but also that it will benefit other patients with the disease”, concludes Mérab Kokaia.
Publication: Dynamic interaction of local and transhemispheric networks is necessary for progressive intensification of hippocampal seizures
Contact:
Fredrik Berglind: fredrik.berglind@med.lu.se
Mérab Kokaia: merab.kokaia@med.lu.se, + 46 70 6620899
FACTS – Epilepsy
Epilepsy can occur at any time of life in any individual. It can be due to a hereditary tendency or the result of an injury. Seizures can vary in frequency from a couple of seizures over a lifetime to several per day. Epileptic seizures are caused by temporary disruptions in the brain’s neurons and always start very suddenly. They last from seconds to minutes and cease of their own accord. Source: Swedish Epilepsy Association
**FACTS – Chemogenetics
Chemogenetics entails transferring a gene for a modified membrane protein (hM4D) to a certain group of neurons in the brain. hM4D cannot be activated by any naturally occurring neurotransmitter, so it does not affect the normal function of the neurons. It is possible to activate hM4D specifically by administering a very low dose of a certain drug, which cannot affect other cells in the brain. Activated hM4D impairs neuron signalling, but once the drug leaves the body, the neurons return to their unaffected state and function normally again. This makes it possible to temporarily reduce epileptic discharges, without affecting normal brain function at other times. The technique for chemogenetics was developed by an American research team.
The researchers used a method known as chemogenetics**, which enables them to reduce activity in the specific areas and nerve cells involved in an epileptic seizure, whereas other parts and cells in the body remain unaffected. This is in contrast to current drugs that affect more or less all parts and cells of the body, potentially leading to side-effects.
“Very few similar studies have been carried out previously, and this is the first study in which we succeeded in reducing the epileptic activity in one area of the brain by using chemogenetics to affect another area, not the seizure focus. This opens up the possibility of treating epilepsy in areas of the brain that cannot be surgically removed or treated directly”, explains Mérab Kokaia.
In Sweden, around 60 000 people currently suffer from epilepsy, of whom around a third have such a severe form of the disease that current treatment with existing drugs does not work.
“We hope that, in the future, this knowledge will help people with this severe form of epilepsy, but also that it will benefit other patients with the disease”, concludes Mérab Kokaia.
Publication: Dynamic interaction of local and transhemispheric networks is necessary for progressive intensification of hippocampal seizures
Contact:
Fredrik Berglind: fredrik.berglind@med.lu.se
Mérab Kokaia: merab.kokaia@med.lu.se, + 46 70 6620899
FACTS – Epilepsy
Epilepsy can occur at any time of life in any individual. It can be due to a hereditary tendency or the result of an injury. Seizures can vary in frequency from a couple of seizures over a lifetime to several per day. Epileptic seizures are caused by temporary disruptions in the brain’s neurons and always start very suddenly. They last from seconds to minutes and cease of their own accord. Source: Swedish Epilepsy Association
**FACTS – Chemogenetics
Chemogenetics entails transferring a gene for a modified membrane protein (hM4D) to a certain group of neurons in the brain. hM4D cannot be activated by any naturally occurring neurotransmitter, so it does not affect the normal function of the neurons. It is possible to activate hM4D specifically by administering a very low dose of a certain drug, which cannot affect other cells in the brain. Activated hM4D impairs neuron signalling, but once the drug leaves the body, the neurons return to their unaffected state and function normally again. This makes it possible to temporarily reduce epileptic discharges, without affecting normal brain function at other times. The technique for chemogenetics was developed by an American research team.